Priced Out of a Lifesaving Drug: The Human Impact of Rising Insulin Costs, Hearing Before the Subcommittee on Oversight and Investigations of the Committee on Energy and Commerce, House of Representatives, One Hundred Sixteenth Congress, First Session, April 2, 2019 [open pdf - 3MB]
This is the April 2, 2019 hearing on "Priced Out of a Lifesaving Drug: The Human Impact of Rising Insulin Costs," held before the House Subcommittee on Oversight and Investigations of the Committee on Energy and Commerce. From the opening statement of Diana DeGette: "We are here this morning to examine the impacts of climbing insulin costs on the seven and a half million people in the United States who rely on insulin every day to manage their blood sugar levels and prevent debilitating complications. Insulin insures the health and well-being for millions of people and for the 1.25 million people with type 1 diabetes it is a life-sustaining drug for which there is no substitute. The scientists who made the discovery of insulin knew of its lifesaving importance. Even nearly a hundred years ago, they were concerned that the discovery would be commercialized to the point of being put out of financial reach for those who needed it. To avoid this, they sold the insulin patent to the University of Toronto for one single dollar. Yet, today, skyrocketing prices are making it unaffordable for millions of people in this country." Statements, letters, and materials submitted for the record include those of the following: Gail deVore, William T. Cefalu, Alvin C. Powers, Kasia J. Lipska, Christel Marchand Aprigliano, and Aaron J. Kowalski.
Serial No. 116-21
U.S. Government Publishing Office: http://www.gpo.gov/